The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Paves the way for next-gen ultra-precise gas sensing
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Workshop on ECG interpretation also marks launch of “Handbook on ECGs – Volume 2”
Panacea Biotec receives LoA from CMSS
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
_256_384.jpg)
Effective recovery at home begins with well-defined care plans that outline treatment protocols, recovery milestones, and monitoring requirements tailored to individual patient needs
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
Subscribe To Our Newsletter & Stay Updated
